Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse
about
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisMicroparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief reviewAdvances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2Influence of treatment on morphological features of mucosal inflammationOral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.Comparison of the effect of mesalazine and sulfasalazine on laboratory parameters: a retrospective observational study.Transcript levels of Toll-Like Receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis.Recent advances in inflammatory bowel disease.Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretionTests of renal function in patients with quiescent colitis: effects of drug treatment.Drug therapy of ulcerative colitisDNA flow cytometric evaluation of cell cycle distribution in ulcerative colitis: a proposed method for assessing severity of disease.Ulcerative colitis: current treatment strategies and future prospects.A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitisIn vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease.Pathology of inflammatory bowel diseases (IBD): variability with time and treatment.Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease.Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis.Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.Peripheral neuropathy and mesalazine.Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitisDigital imaging of colon tissue: method for evaluation of inflammation severity by spatial frequency features of the histological images.Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis.The risks and the benefits of mesalazine as a treatment for ulcerative colitis.One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitisN08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy.Value of colonoscopy for prediction of prognosis in patients with ulcerative colitisRenal effects of long-term treatment with 5-aminosalicylic acidEfficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis.Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates.Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis.A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index.Ratio of Circulating Estrogen Receptors Beta and Alpha (ERβ/ERα) Indicates Endoscopic Activity in Patients with Crohn's Disease.Medical treatment of ulcerative colitis: scoring the advances.Assessment of disease severity and activity in inflammatory bowel disease.A reproducible grading scale for histological assessment of inflammation in ulcerative colitis.
P2860
Q24185876-C6472DFF-A42B-494C-B389-AA786481D368Q24198024-E4C648DE-3377-4BA0-A512-EB0C8B208411Q24246220-0C87F083-33DA-4871-8BB4-4AAB65192591Q24248026-6E517C59-EB00-4498-B998-309B0961FCC3Q26743907-20312D8A-C090-4423-9CC3-C8918378C3EAQ26798299-7FC109AF-6A49-4EF2-AC5B-1ED218307775Q28192791-CA48BA10-948C-4330-87A5-5B588E96DC7CQ31811146-EBEE6575-338A-45D3-A4AE-02F79FA39028Q33401006-E96A1E80-FE49-45C3-9A2F-141415BD6651Q34106945-323804B6-4B86-4D2D-B6E3-D7220B2D2787Q34188405-BAC495A3-2BC4-410C-AE1C-532C84106FC8Q34393049-A3BA8256-9E1A-428A-A9E9-7A1462D3F0FDQ34396529-0DFDAE69-C665-4152-B1AF-342A87E1362DQ34403155-45E046B8-541B-4679-A84E-9FCF7BC9A334Q34407435-CACD9167-F27B-44FC-9109-A6AE67946CD2Q34408967-8AF0FD7C-D53A-441F-911B-639A9B7F7E65Q34409303-A55BB4FB-D3EF-4237-9676-8319BC9E97BAQ35100867-BC58FD92-C8A7-492C-A2BF-52F1A2AB18EEQ35147234-647A8DFF-F220-41DB-8156-50B4FAD9FACAQ35349274-A2C158A3-EF37-48E1-A0D5-4301A85A231AQ35349431-A9D1BD38-7AF1-4D69-A898-A623D4A093D0Q35595076-D86A47F5-B1CC-41AC-8CD8-CBA3DA61C6E4Q35707325-AB0C08FF-0646-45DB-A699-71DA5D18F19FQ35718358-5F6C3170-408B-4B6C-8264-87F8EC560FA5Q35760946-4E407F2E-5DA3-41C1-8585-34518B9922C9Q36062001-3645207B-392F-41BD-BFE9-565DE0AC379BQ36386677-2731548A-EF86-4762-B945-C3ED39395428Q36762423-7D9267B7-D22F-4A1C-A8D8-5A2C5AAA53CAQ37101734-3A15B40A-500D-4186-AA30-6F16AEF28CCCQ37114350-47E3F711-98D6-4E52-83F3-E3DF0B308C09Q37136938-2BC2A43B-AF9E-416E-A8FA-5DC0C714D6ACQ37223156-D3F913E5-74EC-490B-A8D0-169763A62A70Q37853364-C28DFA09-C871-4A7A-9777-15FC6A6861FDQ38212225-A7110FDA-0FC0-4CF8-8D71-AC4FB0887CEDQ38288749-12F1A40D-4B3F-456B-804F-DC43ACBB47E2Q38550845-6604B22D-5621-42AF-9960-A8AEB35F3828Q38617399-7288D25A-7F04-463F-B01F-EB32FA211F09Q39545180-3787E722-60A6-4A3F-BC96-1A4DDE9C3B1FQ40874249-F934FFCB-833C-4909-9E09-97783CC1CA96Q42130317-129137A2-1F19-4CED-9E18-F90E8574159A
P2860
Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse
description
1988 nî lūn-bûn
@nan
1988 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Comparison of delayed release ...... ate ulcerative colitis relapse
@ast
Comparison of delayed release ...... ate ulcerative colitis relapse
@en
Comparison of delayed release 5 aminosalicylic acid
@nl
type
label
Comparison of delayed release ...... ate ulcerative colitis relapse
@ast
Comparison of delayed release ...... ate ulcerative colitis relapse
@en
Comparison of delayed release 5 aminosalicylic acid
@nl
prefLabel
Comparison of delayed release ...... ate ulcerative colitis relapse
@ast
Comparison of delayed release ...... ate ulcerative colitis relapse
@en
Comparison of delayed release 5 aminosalicylic acid
@nl
P2093
P2860
P356
P1433
P1476
Comparison of delayed release ...... ate ulcerative colitis relapse
@en
P2093
P2860
P304
P356
10.1136/GUT.29.5.669
P407
P577
1988-05-01T00:00:00Z